Variants in the CYP3A4 gene significantly affect the metabolism of lumefantrine, altering drug levels and impacting its efficacy and safety, while the role of CYP2D6 is secondary but still contributes to variability in treatment outcomes. These pharmacokinetic gene interactions are crucial for personalizing malaria treatment regimens based on individual genetic profiles.